Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
CMOs showed an increasing reluctance to take on debt in 2022
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Subscribe To Our Newsletter & Stay Updated